Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Vor Biopharma Inc. (Nasdaq: VOR), a clinical‑stage biotech company dedicated to transforming the treatment of autoimmune diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $10.00 per share, generating expected gross proceeds of approximately $100 million (before underwriting discounts and commissions and offering expenses). The company plans to close the offering on or about November 12, 2025, subject to customary closing conditions. In addition, Vor Bio has granted the underwriters a 30‑day option to purchase up to an additional 1,500,000 shares at the public offering price, less underwriting discounts and commissions. All of the shares are being sold by Vor Bio. Joint book‑running managers for the offering include J.P. Morgan Securities LLC, Jefferies LLC, Citigroup Global Markets Inc. and TD Securities (USA) LLC. The offering is being made pursuant to a shelf registration statement previously filed with the U.S. Securities and Exchange Commission, declared effective on March 31, 2025. Vor Bio is advancing its lead candidate, telitacicept, a novel dual‑target fusion protein, through Phase 3 clinical development for serious autoantibody‑driven conditions worldwide. #VorBio #BiotechFunding #AutoimmuneTherapy #Telitacicept #SlimScan #GrowthStocks #CANSLIM